http://www.rxpgnews.com/ Medical News and Information Thu, 21 Aug 2008 02:00:28 PST en-us http://www.rxpgnews.com/tarvacin/Tarvacin_TM_Anti-Viral_Hepatitis_C_Clinical_Progra_3135_3135.shtml Tarvacin Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it has accelerated its clinical program for Tarvacin(TM) Anti-Viral for the treatment of chronic hepatitis C virus infection (HCV). Wed, 18 Jan 2006 18:01:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_Anti-Viral_Hepatitis_C_Clinical_Progra_3135_3135.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_effective_in_controlling_Pancreatic_Cance_3110_3110.shtml Tarvacin Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced preclinical results showing that 3G4, the mouse equivalent of Tarvacin(TM) Anti-Cancer, was effective at controlling the growth and spread of pancreatic cancer as a single agent and had significantly enhanced efficacy when combined with the standard-of-care chemotherapy gemcitabine. Wed, 11 Jan 2006 19:21:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_effective_in_controlling_Pancreatic_Cance_3110_3110.shtml http://www.rxpgnews.com/tarvacin/Peregrine_Pharmaceuticals_Evaluating_Therapeutic_O_2702_2702.shtml Tarvacin Tue, 25 Oct 2005 05:11:00 PST http://www.rxpgnews.com/tarvacin/Peregrine_Pharmaceuticals_Evaluating_Therapeutic_O_2702_2702.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_starts_with_Phase_I_study_against_Hepa_2010_2010.shtml Tarvacin Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), announced today the initiation of a phase I anti-viral study of Tarvacin(TM), the Company's first Anti-Phospholipid Therapy candidate. The phase I study is an open-label, dose-escalation study in up to 32 adult patients with chronic hepatitis C virus (HCV) infection who either no longer respond to or failed standard therapy with pegylated interferon and ribavirin combination therapy. Mon, 08 Aug 2005 17:40:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_starts_with_Phase_I_study_against_Hepa_2010_2010.shtml http://www.rxpgnews.com/tarvacin/New_data_support_broad_anti-viral_potential_of_Tar_1979_1979.shtml Tarvacin The data presented at BIO 2005 showed that Tarvacin(TM) binds to enveloped virus particles representing 6 different virus families, binds to virally infected cells and inhibits viral replication in multiple virus systems. The data also indicated that Tarvacin(TM) provided significant protection against Cytomegalovirus (CMV) and Pichinde virus (an in vivo Lassa fever model) infections. Mon, 01 Aug 2005 00:00:00 PST http://www.rxpgnews.com/tarvacin/New_data_support_broad_anti-viral_potential_of_Tar_1979_1979.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_also_useful_in_imaging_solid_tumors_1978_1978.shtml Tarvacin Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors. Sun, 31 Jul 2005 23:13:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_also_useful_in_imaging_solid_tumors_1978_1978.shtml http://www.rxpgnews.com/tarvacin/Tarvacin_TM_to_be_evaluated_for_the_treatment_of_L_1977_1977.shtml Tarvacin Peregrine Pharmaceuticals Inc. has announced that it has signed a Cooperative Research and Development Agreement (CRADA) for Material Transfer with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of Tarvacin(TM) to treat hemorrhagic diseases resulting from Ebola and Marburg viral infections. Sun, 31 Jul 2005 23:02:00 PST http://www.rxpgnews.com/tarvacin/Tarvacin_TM_to_be_evaluated_for_the_treatment_of_L_1977_1977.shtml